MOK

Across TCGA pan-cancer cohorts, MOK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MOK data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MOK mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MOK expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where MOK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.455	0.767	.007	21	view →
LSCC	DFS	Tertile	II,III,IV	0.811	0.376	.011	20	view →
PDAC	DFS	Quartile	III,IV	0.462	0.968	.010	6	view →
UCEC	OS	Median	All	0.840	0.971	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MOK–LUAD (DFS)

Open the LUAD breakdown →